Publicis

DEAR HEALTH (CONT’D)

20/09/22 -"Over the last three years, AlphaValue has been on a mission to call Health stocks expensive. That segment excludes Pharmas. The sector is down 30%, of which 7% over the last week. That still leaves ..."

PDF page sample
Pages
55
Language
English
Published on
20/09/22
Download
You may also be interested by these reports :
17/10/25
Definitively, investors struggle to make up their minds on Wolters Kluwer (BUY ; Netherlands) status when it relates to Gen AI technology. Since ...
17/10/25
Pearson delivered accelerating Q3 sales growth and left its guidance unchanged for FY25, with further acceleration expected for Q4. The performance ...
16/10/25
Q3 results for Canal+ were reassuring; however, no catalysts are anticipated to boost the stock before the release of the annual accounts in early ...
14/10/25
Once again, Publicis beat expectations with strong organic net revenue growth, led by an acceleration in the US and solid trends in Asia Pacific and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO